IMARC Group, a leading market research company, has recently released a report titled "Sickle Cell Disease Treatment Market Report Size, Share, Trends and Forecast by Treatment Type, End User, and Region, 2025-2033" The study provides a detailed analysis of the industry, including the global sickle cell disease treatment market size, share, trends, growth and forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Sickle Cell Disease Treatment Market Overview

The global sickle cell disease treatment market was valued at USD 4.03 Billion in 2024 and is projected to grow to USD 13.06 Billion by 2033, reflecting a CAGR of 13.26% during the forecast period of 2025-2033. The market growth is driven by the increasing prevalence of sickle cell disease worldwide, advancements in diagnostic and gene therapies, and supportive healthcare policies. North America leads the market with a significant share of around 38.7% in 2024.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Sickle Cell Disease Treatment Market Key Takeaways

• Current Market Size: USD 4.03 Billion in 2024
• CAGR: 13.26% during 2025-2033
• Forecast Period: 2025-2033
• North America dominates with a market share of around 38.7% in 2024, driven by advanced healthcare infrastructure and research.
• The global prevalence of sickle cell disease is increasing, with over 20 million affected worldwide in 2025 and more than 100,000 patients in the USA.
• Blood transfusion accounts for approximately 48.9% market share due to its widespread use as a treatment modality.
• Hospitals lead the end-user segment with around 60.8% market share, providing comprehensive diagnosis and specialized care.
• Increasing disposable incomes and rising awareness are expanding treatment access, particularly in emerging economies.

Request Your Free “Sickle Cell Disease Treatment Market” Insights Sample PDF: https://www.imarcgroup.com/sickle-cell-disease-treatment-market/requestsample

Market Growth Factors

The growth of the market is driven by the increasing prevalence of sickle cell disease. As of 2025, over 20 million people were estimated to have sickle cell disease worldwide thanks to newborn screening and improved disease diagnosis. Improved survival rates exist. Migration causes geographic spread. The number of patients needing curative therapy increases. The number of patients needing supportive therapy increases. Government works and healthcare providers work toward providing more resources and developing new therapies faster.

Emerging markets' increased personal disposable income will possibly let more patients afford advanced treatment opportunities. Personal disposable income in the USA reached USD 22,454.6 Billion in May 2025. This provides patients with access to more services. Specialists and costly therapies such as gene-based therapies are examples. Public health campaigns and advocacy raised awareness in people, leading to early diagnoses, patient engagement, and participation inside clinical trials.

Regulatory authorities are fast-tracking the approval of new therapies citing the need because of disease burden. For example, the U.S. Food and Drug Administration (FDA) approved a SCD pain relieving drug in 2019 and issued Orphan Drug designation for novel gene therapies. A fast track for market authorizations has a positive effect on research and development of new therapies. Cooperation among regulators and safety standards lead to favorable market conditions.

Market Segmentation

Analysis by Treatment Type:

• Blood Transfusion: Leads the market with around 48.9% share in 2024. This widely used treatment reduces sickled red blood cells, improving oxygen delivery and minimizing complications. It is employed both for acute crisis management and long-term prevention, though requires monitoring for adverse effects like iron overload.
• Pharmacotherapy
• Bone Marrow Transplant

Analysis by End User:

• Hospitals: Account for about 60.8% of the market share in 2024. They provide comprehensive diagnosis, emergency care, transfusions, advanced therapies like stem cell transplants, and patient management. Hospitals also serve as referral centers linking patients to clinical trials.
• Diagnostic Centers
• Others

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the largest market share at over 38.7% in 2024, attributable to its advanced healthcare infrastructure, robust research activities, and favorable regulatory environment. Screening programs, early diagnosis, and access to cutting-edge therapies further bolster the region's leadership. Insurance coverage and government health programs improve patient access despite existing disparities. The U.S. specifically accounts for about 89% of North America's market share, benefiting from expanded diagnostic centers and increased treatment adoption.

Recent Developments & News

• June 2025: Ministry of Tribal Affairs and AIIMS Delhi launched a drug development competition targeting sickle cell disease in tribal populations in India, with commitments for full funding and free medicines.
• June 2025: Beam Therapeutics received orphan drug designation from the U.S. FDA for BEAM-101, a genetically modified cell therapy for sickle cell disease.
• May 2025: Indian Council of Medical Research introduced the ICMR-SCD Stigma Scale to address stigma among patients and caregivers in six endemic districts.
• March 2025: UCSF Benioff Children's Hospital Oakland initiated a clinical trial using CRISPR-Cas9 gene-editing to cure sickle cell disease.
• February 2025: CRISPR medicine was developed as the first gene-editing therapy for sickle cell disease, providing new hope for patients.

Key Players

• AstraZeneca Plc
• Baxter International Inc.
• bluebird bio Inc.
• Bristol-Myers Squibb Company
• CRISPR Therapeutics
• Emmaus Medical Inc.
• Global Blood Therapeutics Inc.
• GlycoMimetics Inc.
• Novartis AG
• Pfizer Inc.
• Sangamo Therapeutics

Ask Analyst For Request Customization: https://www.imarcgroup.com/request?type=report&id=4076&flag=E

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: [email protected],

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302